| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.8 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |